Pfizer Stock Drops, PayPal Gains, Stubhub Downgraded | Stock Movers

Pfizer Stock Performance

• 📉 Pfizer shares are down 5.4% due to an expectation of little to no sales growth next year.
• 💰 Revenue for 2026 is projected to be between $59.5 to $62.5 billion, with sales around $62 billion.
• ⚠️ Demand for COVID-19 drugs is fading, and competition in other drug areas is increasing.
• 💸 Pfizer is implementing a significant cost-cutting effort, targeting over $7 billion in savings by 2027.
• 📈 The company is actively seeking acquisitions, particularly in the obesity drug segment.

Stubhub Faces Headwinds

• 📉 Stubhub shares have fallen by nearly 6% following a downgrade by Citizens analysts.
• ⚔️ Key concerns include increasing competition for market share, especially from Vivid Seats.
• ⚖️ Regulation poses a threat, with potential bans on ticket resales above original cost, as seen in the UK.
• IPO performance has been poor, with the stock down over 40% since its initial public offering.

PayPal's Banking Ambitions

• 📈 PayPal shares are up by almost 2% after the company applied to become a bank in the United States.
• 🏦 This move involves submitting applications to the Federal Deposit Insurance Corp. and the Utah Department of Financial Institutions.
• 💡 Analysts view this as a logical step, given PayPal's existing involvement in the lending business.
• ⏳ The timeline for approval is uncertain, with some analysts suggesting it could take several years.